Confronto
Cerebrolysin vs. Epitalon
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
96889-70-6
307297-39-8
Peso molecolare
nessun dato
390.35 g/mol
Emivita
nessun dato
0.3 h
Sequenza
nessun dato
Ala-Glu-Asp-GlyMeccanismo d'azione
Cerebrolysin
Cerebrolysin is a mixture of low-molecular-weight peptides (predominantly below 10 kDa) and free amino acids obtained by enzymatic cleavage of lipid-free porcine brain proteins. The manufacturer and preclinical literature describe a neurotrophic and neuroprotective mode of action said to mimic endogenous neurotrophic factors; cell and animal models have reported effects on neuronal survival, synaptogenesis and anti-apoptotic signalling (including PI3K/Akt). Because it is a complex, incompletely characterised mixture, the precise mechanism in humans remains unclear.
Epitalon
Postulated mechanisms include modulation of gene expression in pinealocytes, telomerase activation (observed in cell culture studies) and influence on melatonin synthesis. A defined primary receptor is not established; the mechanistic basis rests on in-vitro and animal data from the Khavinson group.
Base di evidenze
Evidenza più alta
RCT sull'uomo
Studio sull'uomo
Studi
4
4
di cui sull'uomo
4
1
Effetti registrati
4
4
Contraddizioni aperte
1
1
Eventi avversi documentati
1
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Cerebrolysin and Epitalon?
- Cerebrolysin is classified as "Ricerca (altro)", while Epitalon is classified as "Ricerca (altro)". Cerebrolysin: Cerebrolysin (FPF-1070) is not a single peptide but a porcine-brain-derived preparation of low-molecular-weight peptides and free amino acids, produced by standardised enzymatic proteolysis. It is approved in several countries (including Austria, Russia and parts of Asia) for stroke, dementia and traumatic brain injury, but is not FDA-approved in the United States and not centrally approved by the EMA. Its efficacy is contested: Cochrane systematic reviews found no convincing benefit and flagged possible harm signals. Epitalon: Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal extract epithalamin (V. Khavinson, St. Petersburg). Investigated in the Russian research and anti-ageing context; Western controlled trials are largely absent. No medicines approval in EU or US. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Cerebrolysin or Epitalon?
- The highest available evidence level is "RCT sull'uomo" for Cerebrolysin and "Studio sull'uomo" for Epitalon. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Cerebrolysin and Epitalon in Germany and the United States?
- Germania: Cerebrolysin — Non chiaro, Epitalon — Non approvato. Stati Uniti: Cerebrolysin — Non approvato, Epitalon — Non approvato. These are factual summaries with source and review date on the individual pages.